NEW YORK (GenomeWeb News) – Vermillion today said that its unsecured creditors have "overwhelmingly accepted" its First Amended Chapter 11 Plan of Reorganization.

Approval of the plan clears the way for the Fremont, Calif.-based molecular diagnostics firm to proceed to a confirmation hearing for the plan before the US Bankruptcy Court for the District of Delaware. That confirmation hearing is scheduled for tomorrow, Jan. 7.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.